Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.

ABSTRACT:

Background

Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliperidone palmitate have improved treatment adherence and therefore symptoms. However, real-world studies comparing 3-monthly LAI formulations with other LAIs and oral antipsychotics (OAs) are scarce.

Objective

The objective of this study was to investigate and evaluate the clinical effectiveness of paliperidone palmitate LAI monthly (PP1M; Xeplion^®) and 3-monthly (PP3M; Trevicta^®) formulations compared with the monthly LAI aripiprazole (AM; Abilify Maintena^®) and OAs in Spain.

Methods</

SUBMITTER: Gutierrez-Rojas L 

PROVIDER: S-EPMC9095535 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature